US regulatory guidance OCC Bulletin 2026-13, issued jointly by the OCC, Federal Reserve Board, and FDIC on April 17, 2026, explicitly excluded generative and agentic AI models from its scope.

Overview Debates Related claims Topics Sources

Inquiry chair Kate Lampard is considering issuing interim regulations and recommendations regarding Oxevision camera technology to prevent further avoidable patient deaths.

The Medicines and Healthcare products Regulatory Agency requested clinical evidence from manufacturer Lio Health supporting claims that Oxevision reduced self-harm, but Lio Health failed to provide it.

Lawyers representing over 70 bereaved families urged the Lampard Inquiry on October 20, 2026 to recommend a national ban on Oxevision in NHS mental health inpatient wards.

Epic Systems chief security officer Stirling Martin participated in Anthropic's Project Glasswing program to test how attackers could utilize open-source artificial intelligence agents to access confidential health records.

India's Central Drugs Standard Control Organisation requires artificial intelligence developers to demonstrate clinical validity, demographic diversity in training datasets, version control, and post-market surveillance plans.

India's Central Drugs Standard Control Organisation issued guidance in July 2026 establishing approval pathways for Software in a Medical Device and Software as a Medical Device.

Regulatory sandboxes allow health authorities to evaluate rapidly evolving artificial intelligence technologies and balance patient safety against clinical innovation.

A joint report by European science academies proposed regulatory sandboxes as controlled, time-limited environments to test medical artificial intelligence tools under regulatory oversight before clinical deployment.

Sound Practice 10 of the Financial Stability Board's guidance establishes a risk-based intervention model requiring mandatory human sign-off for financial transactions exceeding specific thresholds.

The Financial Stability Board published 12 non-binding recommended practices on October 16, 2026, for the responsible adoption of artificial intelligence in financial institutions across G20 economies.

The OCC, Federal Reserve Board, and FDIC plan a future request for information regarding bank AI model risk management, though no timeline has been set.

The American Medical Association's framework focuses on four questions covering clinical functions, evidence of performance, conditions of permission, and risk accountability.

The Financial Stability Board declined to framing AI systems as synthetic employees, citing concerns that the analogy obscures unpredictable autonomous decisions.

The American Medical Association released a new governance framework on October 15, 2026, to guide the safe deployment of agentic AI assuming clinical functions in healthcare.

In a survey of 250 U.S. healthcare leaders, 28% reported deploying agentic AI tools and 72% reported that agentic AI is occasionally implemented without IT approval.

In a survey of 250 U.S. healthcare leaders, 44% of respondents reported conducting pilots or proof-of-concept projects with agentic AI tools.

Suki plans to use its Series E funding to develop autonomous AI agents to manage post-visit healthcare tasks including referrals, prior authorizations for new medications, filling orders, and scheduling follow-ups.

Suki's planned AI agents will utilize clinical information gathered from the company's existing documentation and point-of-care tools to execute post-visit healthcare tasks.

Suki plans to use its Series E funding to deepen integration with its more than 30 existing health technology partners, including Optum, Zoom, and athenahealth, by embedding new AI agent capabilities.

EHR vendors should be required to provide open access to third-party AI tools